Proteins specifically hyperexpressed in a coeliac disease patient with aberrant T cells

Clinical and Experimental Immunology

Volumn 148, Issue 3, 2007, Pages 402-409

  De Re, V ^a   Simula, M P ^a   Caggiari, L ^a   Orzes, N ^b   Spina, M ^a   Da Ponte, A ^a   De Appollonia, L ^a   Dolcetti, R ^a   Canzonieri, V ^a   Cannizzaro, R ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b Presidio Ospedaliero   (Italy)

Author keywords

Coeliac disease; Immunology; MALDI TOF analysis; Protein profile; T cell receptor

Indexed keywords

APOLIPOPROTEIN C3; CELL PROTEIN; CHARCOT LEYDEN CRYSTAL PROTEIN; GALECTIN; IMMUNOGLOBULIN M; T LYMPHOCYTE RECEPTOR GAMMA CHAIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELIAC DISEASE; CELL CLONE; COMPARATIVE STUDY; CONTROLLED STUDY; CRYSTAL STRUCTURE; DUODENUM BIOPSY; FEMALE; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; T LYMPHOCYTE; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ADULT; APOLIPOPROTEIN C-III; CELIAC DISEASE; DUODENUM; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNOGLOBULIN M; LYSOPHOSPHOLIPASE; MIDDLE AGED; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; T-LYMPHOCYTE SUBSETS;

EID: 34247872893     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2007.03348.x     Document Type: Article

References (48)

1. Cellier C, Delabesse E, Helmer C et al. Refractory sprue, coeliac disease, and enteropathy-associated T cell lymphoma. French Coeliac Disease Study Group. Lancet 2000 356:203 8.
2. Dieterich W, Ehnis T, Bauer M et al. Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med 1997 3:797 801.
3. Vader W, Stepniak D, Kooy Y et al. The HLA-DQ2 gene dose effect in celiac disease is directly related to the magnitude and breadth of gluten-specific T cell responses. Proc Natl Acad Sci USA 2003 100:12390 5.
4. Lundin KE, Farstad IN, Raki M et al. Alemtuzumab treatment of refractory celiac disease type II. Gastroenterology 2006 130 (Suppl. 2 A 666 [Abstract].
5. Verbeek WH, Mulder CJ, Zweegman S. Alemtuzumab for refractory celiac disease. N Engl J Med 2006 355:1396 7.
6. Vivas S, Ruiz de Morales JM, Ramos F, Suarez-Vilela D. Alemtuzumab for refractory celiac disease in a patient at risk for enteropathy-associated T cell lymphoma. N Engl J Med 2006 354:2514 15.
7. Keating MJ, Flinn I, Jain V et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002 99:3554 61.
8. Lundin J, Osterborg A, Brittinger G et al. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. J Clin Oncol 1998 16:3257 63.
9. Oberhuber G, Granditsch G, Vogelsang H. The histopathology of coeliac disease: time for a standardized report scheme for pathologists. Eur J Gastroenterol Hepatol 1999 11:1185 94.
10. De Re V, Caggiari L, De Vita S et al. Genetic insights into the disease mechanisms of type II mixed cryoglobulinemia induced by hepatitis C virus. Dig Liver Dis in press.
11. De Re V, De Vita S, Sansonno D et al. Type II. mixed cryoglobulinaemia as an oligo rather than a mono B-cell disorder: evidence from GeneScan and MALDI-TOF analyses. Rheumatology 2006 45:685 93.
12. Wood GM, Shires S, Howdle PD, Losowsky MS. Immunoglobulin production by coeliac biopsies in organ culture. Gut 1986 27:1151 60.
13. O'Mahony S, Arranz E, Barton JR, Ferguson A. Dissociation between systemic and mucosal humoral immune responses in coeliac disease. Gut 1991 32:29 35.
14. Wood GM, Howdle PD, Trejdosiewicz LK, Losowsky MS. Jejunal plasma cells and in vitro immunoglobulin production in adult coeliac disease. Clin Exp Immunol 1987 69:123 32.
15. Lancaster-Smith M, Joyce S, Kumar P. Immunoglobulins in the jejunal mucosa in adult coeliac disease and dermatitis herpetiformis after the reintroduction of dietary gluten. Gut 1977 18:887 91.
16. Lancaster-Smith M, Packer S, Kumar PJ, Harries JT. Cellular infiltrate of the jejunum after re-introduction of dietary gluten in children with treated coeliac disease. J Clin Pathol 1976 29:587 91.
17. Kett K, Scott H, Fausa O, Brandtzaeg P. Secretory immunity in celiac disease: cellular expression of immunoglobulin A subclass and joining chain. Gastroenterology 1990 99:386 92.
18. Brandtzaeg P, Halstensen TS, Kett K et al. Immunobiology and immunopathology of human gut mucosa: humoral immunity and intraepithelial lymphocytes. Gastroenterology 1989 97:1562 84.
19. Crabtree JE, Heatley RV, Losowsky ML. Immunoglobulin secretion by isolated intestinal lymphocytes: spontaneous production and T cell regulation in normal small intestine and in patients with coeliac disease. Gut 1989 30:347 54.
20. Scott BB, Scott DG, Losowsky MS. Jejunal mucosal immunoglobulins and complement in untreated coeliac disease. J Pathol 1977 121:219 23.
21. Halstensen TS, Hvatum M, Scott H, Fausa O, Brandtzaeg P. Association of subepithelial deposition of activated complement and immunoglobulin G and M response to gluten in celiac disease. Gastroenterology 1992 102:751 9.
22. Moorthy AV, Zimmerman SW, Maxim PE. Dermatitis herpetiformis and celiac disease: association with glomerulonephritis, hypocomplementia, and circulating immune complexes. JAMA 1978 239:2019 20.
23. Lavo B, Knutson L, Loof L, Hallgren R. Gliadin challenge-induced jejunal prostaglandin E2 secretion in celiac disease. Gastroenterology 2006 99:703 7.
24. Hallgren R, Colombel JF, Dahl R et al. Studies on the secretion rate and immunohistochemical localization of granulocyte granule constituents. Am J Med 1989 86:56 64.
25. Kristjansson G, Hogman M, Venge P, Hallgren R. TI - gut mucosal granulocyte activation precedes nitric oxide production: studies in coeliac patients challenged with gluten and corn. Gut 2005 54:769 74.
26. Colombel JF, Torpier G, Janin A, Klein O, Cortot A, Capron M. Evidence for a local release of major basic protein. Gut 1992 33:1190 4.
27. Mauger JF, Couture P, Bergeron N, Lamarche B. Apolipoprotein C-III isoforms: kinetics and relative implication in lipid metabolism. J Lipid Res 2006 47:1212 8.
28. Khovidhunkit W, Kim MS, Memon RA et al. TI - effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res 2004 45:1169 96.
29. Miller YI, Chang MK, Binder CJ, Shaw PX, Witztum JL. TI - oxidized low density lipoprotein and innate immune receptors. Curr Opin Lipidol 2003 14:437 45.
30. Karlsson H, Leanderson P, Tagesson C, Lindahl M. Mapping of proteins in low-density lipoprotein using two-dimensional gel electrophoresis and mass spectrometry. Proteomics 2005 5:551 65.
31. Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP. Function and regulation by innate cytokines. Annu Rev Immunol 1999 17:189 220.
32. Yasumasu T, Takahara K, Sadayasu T et al. Effect of plasma lipoproteins on natural killer cell activity in the elderly population. J Gerontol A Biosci Med Sci 2006 58:561 5.
33. Zhou X, Paulsson G, Stemme S, Hansson GK. TI - hypercholesterolemia is associated with a T helper (Th)1/Th2 switch of the autoimmune response in atherosclerotic apo E-knockout mice. J Clin Invest 1998 101:1717 25.
34. Cabana VG, Siegel JN, Sabesin SM. TI - effects of the acute phase response on the concentration and density distribution of plasma lipids and apolipoproteins. J Lipid Res 1989 30:39 49.
35. Feingold KR, Hardardottir I, Memon R et al. Effect of endotoxin on cholesterol biosynthesis and distribution in serum lipoproteins in Syrian hamsters. J Lipid Res 2006 34:2147 58.
36. Sammalkorpi K, Valtonen V, Kerttula Y, Nikkila E, Taskinen MR. Changes in serum lipoprotein pattern induced by acute infections. Metabolism 2006 37:859 65.
37. Metzger S, Levy Y, Arnon R, Chajek-Shaul T. TI - co-regulation of apo A-I, apo C-III and apo A-IV gene expression in human intestinal biopsies. Eur J Clin Invest 1996 26:71 5.
38. Meresse B, Curran SA, Ciszewski C et al. TI - reprogramming of CTLs into natural killer-like cells in celiac disease. J Exp Med 2006 203:1343 55.
39. Hue S, Mention JJ, Monteiro RC et al. TI - a direct role for NKG2D/MICA interaction in villous atrophy during celiac disease. Immunity 2004 21:361 77.
40. Gumperz JE, Roy C, Makowska A et al. TI - murine CD1d-restricted T cell recognition of cellular lipids. Immunity 2000 12:211 21.
41. Champagne E, Martinez LO, Vantourout P, Collet X, Barbaras R. TI - role of apolipoproteins in gammadelta and NKT cell-mediated innate immunity. Immunol Res 2005 33:241 55.
42. Scotet E, Martinez LO, Grant E et al. TI - tumor recognition following Vgamma9Vdelta2 T cell receptor interactions with a surface F1-ATPase-related structure and apolipoprotein A-I. Immunity 2005 22:71 80.
43. Bonneville M, Scotet E. TI - synergism and complementarity between human CD1 and MHC-restricted T cells, two lymphoid subsets directed against distinct antigenic worlds. Front Biosci 2005 10:596 607.
44. Ackerman SJ, Liu L, Kwatia MA et al. TI - Charcot-Leyden crystal protein (galectin-10) is not a dual function galectin with lysophospholipase activity but binds a lysophospholipase inhibitor in a novel structural fashion. J Biol Chem 2002 277:14859 68.
45. Furuta GT, Nieuwenhuis EE, Karhausen J et al. Role for major basic protein. Am J Physiol Gastrointest Liver Physiol 2005 289:890 7.
46. Lombardi C, Passalacqua G. Clinical revision of 1862 cases. Arch Intern Med 2003 63:1371 3.
47. Desreumaux P, Janin A, Colombel JF et al. TI - interleukin 5 messenger RNA expression by eosinophils in the intestinal mucosa of patients with coeliac disease. J Exp Med 1992 175:293 6.
48. Lamkhioued B, Gounni AS, Aldebert D et al. TI - synthesis of type 1 (IFN gamma) and type 2 (IL-4, IL-5, and IL-10) cytokines by human eosinophils. Ann NY Acad Sci 1996 796:203 8.